Conning Forecasts Long-Term Expansion for U.S. Life Settlement Market

Conning's study projects long-term expansion in the U.S. life settlement market through 2035, supported by demand for low-correlated alternative assets, an aging population, and rising retirement and long-term-care funding needs. Conning also flags policy supply, insurer exposure, financing, and longevity risks as challenges; the article provides no forecast volume figures.

Analysis

The investable signal is less “alternative assets are attractive” than a possible change in the supply and pricing of policies. If consumer access improves, more policies could reach settlement rather than lapse; however, broader buyer competition may bid up acquisition prices and compress investor returns before market volume shows up in reported results. Aging and long-term-care costs support supply, while stronger universal-life crediting rates could reduce the economic pressure to sell or lapse some policies. These forces pull in opposite directions.

The key second-order risk is longevity-model error: longer policy durations tie up capital, increase funding costs and can erode realized returns even when mortality assumptions initially look favorable. A low correlation label does not remove liquidity, financing, insurer-crediting, or model risk. The press release provides no forecast figures, realized returns, or evidence of investable scale, so it is not a standalone catalyst for asset-manager or insurer earnings.

Near term, likely limited market impact. Over 1–3 months, verify the study’s actual volume and gross-potential forecasts and whether recent settlements show rising policy prices or changing duration assumptions. Over 6–18 months, monitor whether expanded access produces profitable deployments or merely more competition for the same policy supply. No direct public-equity trade is justified from this release alone; the opportunity is primarily a diligence and monitoring signal.

Key Decisions for Investors

• No immediate position: treat the release as industry commentary, not independently verified evidence of earnings growth or attractive fund returns.
• Request the underlying study’s annual settlement-volume forecasts, policy acquisition pricing, realized versus underwritten longevity, financing assumptions, and sensitivity to higher crediting rates before underwriting exposure to life-settlement funds or managers.
• Watch for the key divergence: rising settlement volume alongside stable or improving investor returns would validate scalable growth; rising volume with higher purchase prices, longer durations, or weaker realized returns would indicate competition is absorbing the benefit.
• For any future exposure, require explicit stress tests for longevity extension, funding-cost increases, and slower policy resale or cash realization; these are the main mechanisms that could turn low market correlation into poor liquidity-adjusted returns.